Inhibition of human phosphodiesterase 4A expressed in yeast cell GL62 by theophylline, rolipram, and acetamide-45

Acta Pharmacologica Sinica

Volumn 23, Issue 11, 2002, Pages 1013-1017

  Wang, Kai ^a   Chen, Ji Qiang ^a   Chen, Zhong ^a   Chen, Jun Chun ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

3 ,5 cyclic nucleotide phosphodiesterase; Acetamide 45; Cyclic AMP; Cyclic GMP; Rolipram; Saccharomyces cerevisiae; Theophylline

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ACETAMIDE DERIVATIVE; CYCLIC AMP; CYCLIC GMP; PHOSPHODIESTERASE IV; ROLIPRAM; THEOPHYLLINE;

ARTICLE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME MECHANISM; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PLASMID; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; YEAST CELL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACETAMIDES; GENE EXPRESSION; HUMANS; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; SACCHAROMYCES CEREVISIAE; THEOPHYLLINE; TRANSFECTION;

EID: 0036842355     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Torphy TJ. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-70.
2. Muller T, Engels P, Fozard JR. Subtypes of the type 4 cAMP phosphodiesterase: Structure, regulation and selective inhibition. Trends Pharmacol Sci 1996; 17: 294-8.
3. Souness JE, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman MN, et al. Suppression of eosinophil function by RP73401, a potent and selective inhibitor of cyclic AMP specific phosphodiesterase: Comparison with rolipram. Br J Pharmacol 1995; 115: 39-46.
4. Goncalves de Moraes VL, Singer M, Vargaftig BB, Chignard M. Effects of rolipram on cyclic AMP levels in alveolar marcrophages and lipopolysaccharide-induced inflammation in mouse lung. Br J Pharmacol 1998; 123: 631-6.
5. Shichijo M, Inagaki N, Kimata M, Serzawa I, Saito H, Nagai H. Role of cyclic 3′, 5′-adensine monophosphate in the regulation of chemical mediator release and cytokine production from cultured human mast cells. J Allergy Clin Immunol 1999; 103: S421-8.
6. Essayan DM, Huang SK, Kagey-Sobotka A, Lichtenstein LM. Differential efficacy of lymphocyte- and monocyteselective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J Allergy Clin Immunol 1997; 99: 28-37.
7. Obernolte R, Ratzliff J, Baecker PA, Daniels DV, Zuppan P, Jarnagin K, et al. Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis. Biochim Biophys Acta 1997; 1353: 287-97.
8. Jacobitz S, McLauhlin MM, Livi GP, Burman M, Torphy TJ. Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 1996; 50: 891-9.
9. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
10. Juilfs DM, Soderling S, Burns F, Beavo JA. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 1999; 135: 67-104.
11. Mark A. Phosphodiesterase 4 inhibitors and the treatment of asthma. Drugs 2000; 59: 193-212.
12. Menciu C, Duflos M, Fouchard F, Le Baut G, Emig P, Achterrath U, et al. New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents. J Med Chem 1999; 42: 638-48.
13. Lu YB, Chen Z, Wu M. Acetamide-45 inhibits histamineand methacholine-induced contraction of isolated guinea pig trachea. Acta Pharmacol Sin 2002; 23: 152-6.